Well Referenced

Tag: androgenetic alopecia

An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia

This randomized, open-label, multicenter study evaluated the efficacy of a 0.2% caffeine-based topical solution compared to the standard 5% minoxidil solution in 210 male patients with androgenetic alopecia over a 6-month period. The primary endpoint was the percentage change in the proportion of anagen hairs, assessed via frontal and occipital

Read More »
June 26, 2025 No Comments

Topical Minoxidil Fortified with Finasteride: An Account of Maintenance of Hair Density After Replacing Oral Finasteride

This 2015 retrospective study evaluated the maintenance of hair density in 50 male patients with androgenetic alopecia (AGA) who transitioned from oral finasteride to a topical formulation containing 5% minoxidil and 0.1% finasteride. After two years of oral finasteride and minoxidil therapy, patients switched to the topical regimen. Results showed

Read More »
June 26, 2025 No Comments

Pharmacologic Interventions in Aging Hair

This 2006 review by Dr. Ralph M. Trüeb addresses the biological and environmental contributors to hair aging, including genetic factors, hormonal changes, oxidative stress, and UV radiation. The article outlines established pharmacologic treatments such as topical minoxidil and oral finasteride, which are effective for androgenetic alopecia and age-related hair thinning.

Read More »
June 26, 2025 No Comments

Low-Level Laser (Light) Therapy (LLLT) for Treatment of Hair Loss

This 2014 review by Avci et al. analyzed the efficacy of low-level laser therapy (LLLT) for treating hair loss, including androgenetic alopecia and alopecia areata. The review encompassed preclinical and clinical studies, showing that LLLT can stimulate hair regrowth in both animal models (e.g., chemotherapy-induced alopecia in mice) and humans.

Read More »
June 26, 2025 No Comments

Efficacy of Non-Surgical Treatments for Androgenetic Alopecia: A Systematic Review and Network Meta-Analysis

This 2018 systematic review and network meta-analysis evaluated the comparative effectiveness of six non-surgical treatments for androgenetic alopecia (AGA): dutasteride 0.5 mg, finasteride 1 mg, low-level laser therapy (LLLT), minoxidil 2%, minoxidil 5%, and platelet-rich plasma (PRP). The review included 78 studies, with 22 qualifying for quantitative synthesis. LLLT demonstrated

Read More »
June 26, 2025 No Comments

The Efficacy and Use of Finasteride in Women: A Systematic Review

This 2019 systematic review evaluated the use of finasteride in women for treating hair disorders such as female pattern hair loss (FPHL), frontal fibrosing alopecia (FFA), and lichen planopilaris. It included various study designs—mainly observational—with treatment doses ranging from 0.5 mg to 5 mg daily and durations spanning 6 to

Read More »
June 26, 2025 No Comments

Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

This 2018 randomized controlled trial evaluated sexual adverse events in 117 men aged 23–50 receiving dutasteride 0.5 mg daily for androgenetic alopecia. During the 24-week double-blind phase, sexual adverse events (impotence, decreased libido, ejaculation disorders) occurred in 16% of the dutasteride group versus 8% in the placebo group. In the

Read More »
June 26, 2025 No Comments

A new look at the 5alpha-reductase inhibitor finasteride

This 2006 review published in CNS Drug Reviews (PMID: 16834758) evaluates the broader pharmacological effects of finasteride, a 5α-reductase inhibitor used to treat benign prostatic hyperplasia and androgenetic alopecia. Beyond reducing dihydrotestosterone (DHT), finasteride alters the metabolism of neuroactive steroids like allopregnanolone, impacting GABAergic neurotransmission. These neurosteroid shifts have been

Read More »
June 26, 2025 No Comments